Therapeutics

Rajpal shares his perspectives on the newly FDA-approved treatment, clinical benefits, and its potential impact on keratoconus management.

The CNPV program was announced by the FDA in June 2025 and offers companies the opportunity to reduce standard application review times from 10–12 months to just 1–2 months.

Punctal occlusion may reduce reactions without worsening symptoms

The incision-free therapeutic for keratoconus is expected to be commercially available in early 2026, according to the company.

Real-world insights emphasize identifying underlying causes to tailor treatment.

Oculis plans to commence its PIONEER program, consisting of 3 trials, by the end of the year.

Phentolamine ophthalmic solution 0.75% is for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.

Understand the anatomical risks, technique-specific benefits, and patient selection criteria

Advances address a need for the growing populace with age-related near vision loss.

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

Marguerite B. McDonald, MD, FACS, shares a front-row view of ophthalmology’s “revolution with a capital R."

Tirzepatide and semaglutide show favorable ocular safety compared to traditional weight loss formulations

The annual Best Hospitals report from US News & World Report compares more than 4500 hospitals across 15 specialties and 22 procedures and conditions.

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization in ophthalmology research.

Pinguecula is a benign, common degeneration of the conjunctiva that appears as a grey-white-yellow mass on the bulbar conjunctiva.

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations that defined modern ophthalmology.

New technologies and a proactive mindset are transforming how glaucoma is diagnosed and treated—and redefining what “controlled” really means.

Intracameral tPA can treat fibrinous clots in severe anterior uveitis.

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.

Timely diagnosis and personalized treatment are key to improving visual outcomes.

Amneal Pharmaceuticals received FDA approval for its prednisolone acetate ophthalmic suspension, a steroid eye inflammation treatment referencing Allergan’s Pred Forte, with a US launch planned for Q3 2025.

Harrow expects BYQLOVI to be commercially available in the fourth quarter of 2025.